Download PDF
Aktuelle Urol 2002; 33(6): 435-441
DOI: 10.1055/s-2002-35020
Übersichtsarbeit
© Georg Thieme Verlag Stuttgart · New York

Genitale Infektionen mit humanen Papillomaviren (HPV)

Genital Infections Caused by Human Papillomaviruses (HPV)H.  Büttner1 , D.  Jocham1 , A.  Böhle1
  • 1Klinik und Poliklinik für Urologie, Universitätsklinikum Lübeck (Direktor: Prof. Dr. med. D. Jocham)
Further Information

Publication History

Publication Date:
25 October 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Condylomata acuminata sind die häufigste Ausdrucksform genitoanaler Infektionen mit humanen Papillomaviren (HPV). Zugleich stellt diese Infektion die häufigste sexuell übertragbare Erkrankung dar. Unter den derzeit mehr als 100 bekannten Subtypen finden sich so genannte Low-risk-Typen (vornehmlich HPV 6 und 11), die externe genitoanale Warzen hervorrufen und onkogene High-risk-Typen (insbesondere HPV 13, 16, 18, 31, 33 und 35), die in bis zu 100 % aller Fälle mit prämalignen und invasiven Läsionen des Genitoanalbereiches assoziiert sind. Die aktuellen diagnostischen Verfahren wie auch die derzeitig verfügbaren Therapiemodalitäten werden dargestellt. Die meisten Verfahren führen zu einer lokalen Gewebezerstörung, entweder durch zytotoxische Wirkung oder physikalisch-ablativ. Interferone besitzen antivirale, antiproliferative und immunmodulatorische Eigenschaften, doch führen diese bisher nicht zu effektiven Heilungsraten. Allen gängigen Therapieverfahren eigen sind zudem hohe Rezidivraten gemeinsam. Einen Ausblick stellen innovative immuntherapeutische Ansätze sowie die Darstellung der Vakzinierungsstrategien dieser weltweit an Bedeutung zunehmenden Infektionen dar.

Abstract

Condylomata acuminata are the most prevalent expression of genito-anal infections caused by human papillomavirus (HPV), the most common sexually transmitted disease. To date more than 100 subtypes are classified among which the high-risk-types (HPV 6 and 11) are mostly associated with genital warts. Oncogenic high-risk HPV (13, 16, 18, 31, 33 and 35) are found in premalign and malign genito-anal lesions. Although many treatments are available for genital warts, none are uniformly successful in the treatment of this disease. Most current treatment options work by destroying affected tissue, either by a cytotoxic or a physically ablative mode of action. Interferons have antiviral, antiproliferative, and immunomodulatory activities, but these have not translated into a high level of cure rates against warts. With all current treatments, recurrent warts are common. New treatment modalities focus on activating the host's immune system and perhaps the most effective means for managing HPV disease would be a vaccine that prevents the occurrence of genital warts.

Schlüsselwörter

Genitalwarzen - Condylomata acuminata - Diagnose - Therapie - humane Papillomaviren

Key words

Genital warts - condylomata acuminata - diagnosis - therapy - human papillomavirus

Literatur

  • 1 Bosch F X, Manos M M, Munoz N, Sherman M, Jansen A M, Peto J, Schiffman M H, Moreno V, Kurman R, Shah K V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.  J Natl Cancer Inst. 1995;  87 796-802
    CrossrefPubMedGoogle Scholar
  • 2 Walboomers J M, Jacobs M V, Manos M M, Bosch F X, Kummer J A, Shah K V, Snijders P F, Peto J, Meijer C J, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.  J Pathol. 1999;  189 12-19
    Google Scholar
  • 3 Frisch M, Fenger C, van den Brule A J, Sorensen P, Meijer C J, Walboomers J M, Adami H O, Melbye M, Glimelius B. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomavirus.  Cancer Res. 1999;  59 753-757
    PubMedGoogle Scholar
  • 4 Andersson S, Rylander E, Larsson B, Strand A, Silfversvärd D, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis.  Eur J Cancer. 2001;  37 246-250
    CrossrefPubMedGoogle Scholar
  • 5 Cupp M R, Malek R S, Goellner J R, Smith T F, Espy M J. The detection of human papillomavirus deoxyribonucleide acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis.  J Urol. 1995;  154 1024-1029
    PubMedGoogle Scholar
  • 6 Walboomers J M. Human papillomavirus detection and cervical cancer screening.  Pathologia. 1999;  32 270
    PubMedGoogle Scholar
  • 7 Koutsky L A. Epidemiology of genital human papillomavirus infection.  Am J Med. 1997;  102 3-8
    PubMedGoogle Scholar
  • 8 Jacobs M V, Walboomers J M, Snijders P J, Voorhorst F J, Verheijen R H, Fransen-Daalmeijer N, Meijer C J. Distribution of 37 mucosatropic HPV types in women with cytologically normal cervical smears: the age-related pattern for high-risk and low-risk-types.  Int J Cancer. 2000;  87 221-227
    CrossrefPubMedGoogle Scholar
  • 9 Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Boden E, Rylander E, Wadell G. Lifetime number of partners as the only independent risk factor for human papillomavirus-infection: a population based study.  Sex Transm Dis. 1995;  22 119-126
    PubMedGoogle Scholar
  • 10 Ishi K, Suzuki F, Saito A, Kubota T. Prevalence of human papillomavirus, Chlamydia trachomatis, and Neisseria gonorrhoeae in commercial sex workers in Japan.  Infect Dis Obstet Gynecol. 2000;  8 235-239
    CrossrefPubMedGoogle Scholar
  • 11 Silins I, Kallins I, Dillner J. Correlates of the spread of human papillomavirus infection.  Cancer Epidemiol Biomarkers Prev. 2000;  9 953-959
    PubMedGoogle Scholar
  • 12 Ylitalo N, Josefsson A, Melbye M, Sorensen P, Frisch M, Andersen P K, Sparen P, Gustafsson M, Magnusson P, Ponten J, Gyllensten U, Adami H O. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ.  Cancer Res. 2000;  60 6027-6032
    PubMedGoogle Scholar
  • 13 Eluf-Neto J, Nascimento C M. Cervical cancer in Latin America.  Semin Oncol. 2001;  28 188-197
    CrossrefPubMedGoogle Scholar
  • 14 Mork J, Lie A K, Glattre E, Hallmans G, Jellum E, Koskela P, Moller B, Pukkala E, Schiller Y T, Youngman L, Lehtinen M, Dillner J, Clark S, Wang Z. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.  N Engl J Med. 2001;  344 1125-1131
    CrossrefPubMedGoogle Scholar
  • 15 Gillison M L, Shah K V. Human papillomvirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers.  Curr Opin Oncol. 2001;  13 183-188
    CrossrefPubMedGoogle Scholar
  • 16 Griffiths T RL, Mellon J K. Human papillomavirus and urological tumours: I. Basic science and role in penile cancer.  BJU Int. 1999;  84 (Suppl) 579-586
    CrossrefPubMedGoogle Scholar
  • 17 Griffiths T RL, Mellon J K. Human papillomvirus and urological tumours: II. Role in bladder, prostate, renal and testicular cancer.  BJU International. 2000;  85 211-217
    CrossrefPubMedGoogle Scholar
  • 18 Westend P J, Stoop J A, Hendriks J GM. Human papillomaviruses 6/11, 168 and 31/33/51 are not associated with squamous cell carcinoma of the urinary bladder.  BJU International. 2001;  88 198-201
    CrossrefPubMedGoogle Scholar
  • 19 Coleman N, Birley H D, Renton A M, Hanna N F, Ryait B K, Byrne M, Tasylor-Robinson D, Stanley M A. Immunological events in regressing genital warts.  Am J Clin Pathol. 1994;  102 768-774
    PubMedGoogle Scholar
  • 20 Malejczyk J, Majewski S, Jablonska S. The regulatory influence of immunological host responses. In: Gross G, von Krogh G (Hrsg.). Human Papillomavirus Infections in Dermatovenerology. Coba Raton: CRC Press 1995: 203-226
    Google Scholar
  • 21 Rudlinger R, Smith I, Bunney M, Hunter J. Human papillomavirus infections in a group of renal transplant patients.  Br J Derm. 1986;  115 681-692
    PubMedGoogle Scholar
  • 22 West A F, Leung H Y, Powell P H. Pan-urethral warts as a cause of acute retention of urine.  BJU International. 1999;  84 1100-1101
    CrossrefPubMedGoogle Scholar
  • 23 Rosemberg S K. Subclinical papilloma viral infection of male genitalia.  Urology. 1985;  26 554-557
    CrossrefPubMedGoogle Scholar
  • 24 Fehr M K, Champman C F, Krasieva T, Tromberg B J, McCullogh J L, Berns M W, Tadir Y. Selective photosensitizer distribution in vulvar condyloma acuminatum after topical application of 5-aminolevulinic acid.  Am J Obstet Gynecol. 1996;  174 951-957
    PubMedGoogle Scholar
  • 25 Ross E V, Romero R, Kollias N, Crum C, Anderson R R. Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5-aminolyevulinic acid: implications for photodynamic treatment.  Br J Dermatol. 1997;  137 736-742
    CrossrefPubMedGoogle Scholar
  • 26 Schneede P, Leunig A, Hillemanns P, Wagner S, Hofstetter A G. Photodynamic investigation of mucosa-associated human papillomavirus efflorescence.  BJU International. 2001;  88 117-119
    CrossrefPubMedGoogle Scholar
  • 27 Gross G, Korting H C, Schöfer H, Szeimies R M, Eibisch M A, Ikenberg H, Petry K U, Schneede-Pfister H. Leitlinie der Deutschen STD-Gesellschaft (DSTDG) Condylomata acuminata und andere HPV-assoziierte Krankheitsbilder des Genitale und der Harnröhre. URL: www-duk.med.uni-rostock.de/duk_hpv.htm#Kopf1. 2000
    Google Scholar
  • 28 Ledger W J, Jeremias J, Witkin S S. Testing for high-risk human papillomavirus types will become a standard for clinical care.  Am J Obstet Gynecol. 2000;  182 860-865
    PubMedGoogle Scholar
  • 29 Brennan M M, Lambkin H A, Sheehan C D, Ryan D D, O'Connor T C, Kealy W F. Detection of high-risk subtypes of human papillomavirus in cervical swabs: routine use of the Digene Hybrid Capture assay and polymerase chain reaction analysis.  Br J Biomed Sci. 2001;  58 24-29
    PubMedGoogle Scholar
  • 30 Fralick R A, Malek R S, Goeller J R, Hyland K M. Urethroscopy and urethral cytology in men with external genital condyloma.  Urology. 1994;  43 361-364
    CrossrefPubMedGoogle Scholar
  • 31 Zvulunov A, Medvedovsky E, Biton A, Horowitz S, Vardy D. Association of Ureaplasma uralyticum colonization in male urethra and Condyloma acuminatum.  Isr Med Assoc J. 2000;  2 580-582
    PubMedGoogle Scholar
  • 32 Lorenzato F, Ho L, Terry G, Singer A, Santos L C, De Lucena Batista R, Lubambo T. The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil).  Int J Gynecol Cancer. 2000;  10 143-150
    CrossrefPubMedGoogle Scholar
  • 33 Nathan P M, Thompson V C, Sharmacharja G, Hawkswell J, Fogarty B. A study of the prevalence of male intrameatal warts using meatoscopy in a genitourinary medicine department.  Int J STD AIDS. 1995;  6 184-187
    PubMedGoogle Scholar
  • 34 Kaplinsky R S, Pranikoff K, Chasan S, DeBerry J L. Indications for urethroscopy in male patients with penile condylomata.  J Urol. 1995;  153 1120-1121
    PubMedGoogle Scholar
  • 35 von Krogh G, Lacey C J, Gross G, Barrasso R, Schneider A. European Course on HPV-Associated Pathology: Guidelines for the diagnosis and management of anogenital warts.  Sex Transm Inf. 2000;  76 162-168
    PubMedGoogle Scholar
  • 36 Beutner K R, Spruance S L, Hougham A J, Fox T L, Owens M L, Douglas Jr J M. Treatment of genital warts with an immune-response modifier (imiquimod).  J Am Acad Dermatol. 1998;  38 230-239
    PubMedGoogle Scholar
  • 37 Perry C M, Lamb H M. Topical imiquimod: a review of its use in genital warts.  Drugs. 1999;  58 375-390
    PubMedGoogle Scholar
  • 38 Langley P C, Tyring S K, Smith M H. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts.  Am J Manag Care. 1999;  5 69-77
    PubMedGoogle Scholar
  • 39 Gross G, Rogozinski T, Schofer H, Jablonska S, Roussaki A, Wohr C, Broska J. Recombinant interferon β gel as an adjuvant in the treatment of recurrent genital warts: results of a placebo-controlled double-blind study in 120 patients.  Dermatology. 1998;  196 330-334
    CrossrefPubMedGoogle Scholar
  • 40 Boehle A, Doehn C, Kausch I, Jocham D. Treatment of recurrent penile condylomata acuminata with external application and intraurethral instillation of bacillus Calmette-Guerin.  J Urol. 1998;  160 394-396
    PubMedGoogle Scholar
  • 41 Boehle A, Büttner H, Jocham D. Primary treatment of condylomata acuminata with viable bacillus Calmette-Guerin.  J Urol. 2001;  165 834-836
    PubMedGoogle Scholar
  • 42 Offringa R, van der Burg S H, Ossendorp F, Toes R EM, Melief C JM. Design and evaluation of antigen-specific vaccination strategies against cancer.  Curr Opin Immunol. 2000;  12 576-582
    CrossrefPubMedGoogle Scholar
  • 43 Borysiewiecz L K, Fiander A, Nimako M, Man S, Wilkinson G W, Westmoreland D, Evans A S, Adams M, Stacey S N, Boursnell M E, Rutherford E, Hickling J K, Inglis S C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.  Lancet. 1996;  347 1523-1527
    CrossrefPubMedGoogle Scholar
  • 44 Steller M A, Gurski K J, Murakami M, Daniel R W, Shah K V, Celis E, Sette A, Trimble E L, Park R C, Marincola F M. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidaed epitope of human papillomavirus type 16 E7.  Clinc Cancer Res. 1998;  4 2103-2109
    PubMedGoogle Scholar
  • 45 De Gruijl T D, Bontkes H J, Walboomers J M, Coursaget P, Stukart M J, Dupuy C, Kueter E, Verheijen R H, Helmerhorst T J, Duggan-Keen M F, Stern P L, Meijer C J, Scheper R J. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.  J Gen Virol. 1999;  80 399-408
    PubMedGoogle Scholar
  • 46 Bontkes H J, de Gruijl T D, Walboomers J M, Schiller J T, Dillner J, Helmerhorst T J, Verheijen R H, Scheper R J, Meijer C J. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.  J Gen Virol. 1999;  80 409-417
    PubMedGoogle Scholar
  • 47 Van Driel W J, Ressing M E, Kenter G G, Brandt R M, Krul E J, van Rossum A B, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam P A, Fleuren G J, Kast W M, Melief C J, Trimbos J B. Vaccination with HPV 16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I - II trial.  Eur J Cancer. 1999;  35 946-952
    CrossrefPubMedGoogle Scholar
  • 48 Ressing M E, van Driel W J, Brandt R M, Kenter G G, de Jong J H, Bauknecht T, Fleuren G J, Hoogerhout P, Offinga R, Sette A, Cilis E, Grey H, Trimbos B J, Kast W M, Melief C J. Detection of T-helper responses, but not of human papillomavirus-specific cytotoxic T-lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.  J Immunother. 2000;  23 255-266
    PubMedGoogle Scholar
  • 49 Thompson H S, Davies M L, Holding F P, Fallon R E, Mann A E, O'Neill T, Roberts J S. Phase I safety and antigenicity of TA-GW: a rebombinant HPV 6 L2E7 vaccine for the treatment of genital warts.  Vaccine. 1999;  17 40-49
    CrossrefPubMedGoogle Scholar
  • 50 Lacey C J, Thompson H S, Monteiro E F, O'Neill T, Davies M L, Holding F P, Fallon R E, Roberts J S. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts.  J Infect Dis. 1999;  179 612-618
    CrossrefPubMedGoogle Scholar
  • 51 Christensen N D, Han R, Cladel C M, Pickel M D. Combination treatment with intralesional cidofvir and vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences.  Antimicrob Agents Chemother. 2001;  45 1201-1209
    CrossrefPubMedGoogle Scholar
  • 52 Beutner K R. Therapeutic Approaches to Genital Warts.  Am J Med. 1997;  102 28-37
    PubMedGoogle Scholar

OA Dr. med. H. Büttner

Klinik und Poliklinik für Urologie · Universitätsklinikum Lübeck

Ratzeburger Allee 160

23538 Lübeck

Phone: 0451/500-6113/6114

Fax: 0451/500-4666

Email: hartwig.buettner@medinf.mu-luebeck.de

      >